WaveMan · Company
INTI · Inhibitor Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INTI Inhibitor Therapeutics (INTI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001042418
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2021-10-01 to 2022-09-30
History
FY Dec 2025$0
FY Dec 2024$0
FY Dec 2023$0
FY Dec 2022$0
FY Dec 2021$0
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 202512.79x
Jun 20250.07x
Mar 20250.04x
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-149.41x
TTM operating cash flow over long-term debt only, 2026-06-30
History
FY Dec 2025-87.60x
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026-149.41x
Mar 2026-103.16x
Dec 2025-87.60x
Sep 2025-76.99x
Jun 2025-64.55x
Mar 2025-57.57x
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025-952.3%
FY Dec 2024-91.9%
FY Dec 2023-44.6%
FY Dec 2022+517.9%
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025-952.3%
Sep 2025-201.0%
Jun 2025-142.0%
Mar 2025-109.8%
Dec 2024-91.9%
Sep 2024-62.6%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-145.6%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-80.4%
FY Dec 2024-45.6%
FY Dec 2023-28.9%
FY Dec 2022+201.2%
FY Dec 2021-313.5%
Jun 2026-145.6%
Mar 2026-113.0%
Dec 2025-80.4%
Sep 2025-71.5%
Jun 2025-62.2%
Mar 2025-53.5%
Dec 2024-45.6%
Sep 2024-38.4%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-159.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-101.8%
FY Dec 2024-55.1%
FY Dec 2023-34.8%
FY Dec 2022-12.3%
FY Dec 2021n/a
Jun 2026-159.4%
Mar 2026-126.3%
Dec 2025-101.8%
Sep 2025-76.1%
Jun 2025-67.3%
Mar 2025-59.0%
Dec 2024-55.1%
Sep 2024-43.5%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$16.5M
market value at close 2026-10-09 on 2026-08-14 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
History
FY Dec 2025$5.4M
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026$13.3M
Mar 2026$17.5M
Dec 2025$5.4M
Sep 2025$5.7M
Jun 2025$3.6M
Mar 2025$4.4M
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

INTI Stock Sonar score 3/7 axes

Find similar shapesCompare

INTI ranks highest on risk and compliance (85th percentile) and profitability (15th), and lowest on financial health (6th), among Pharma & Biotech peers.

Profitability
15
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-145.6% · 16 pct, sector of 693
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-159.4% · 15 pct, sector of 578
Financial health
6
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-149.41x · 6 pct, sector of 371
Risk and compliance
85
Inputs
  • Short interest, % of floatno short interest or no free float on file
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.6% · 85 pct, sector of 512
4 not measured: Growth, Insider conviction, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

What changed in the last 30 days
Nothing new filed in the last 30 days

Watch INTI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+63.3%12M
-33%+13%+60%+107%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Inhibitor Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Inhibitor Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns INTI: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in INTI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

INTI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.1M
$1.1M
$353.4K
-54%
n/a
2024
$1.1M
$1.1M
$359.8K
-39%
n/a
2023
$1.1M
$1.1M
$338.0K
-7%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income$-3.4M$-3.7M$-3.4M$-657.9K
Net income$-3.3M$-3.3M$-3.0M$12.1M
EPS (diluted)-0.02-0.02-0.020.03
Operating cash flow$-3.2M$-3.2M$-2.7M$11.7M
Cash$2.4M$5.6M$8.8M$12.0M
Long-term debt$36.9Kn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies